Literature DB >> 11149418

Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2.

Y Chen1, M Hughes-Fulford.   

Abstract

The low-density lipoprotein receptor (LDLR) pathway provides cells with essential fatty acids for prostaglandin E2 (PGE2) synthesis. Regulation of LDLR expression by LDL was compared between the human normal and cancer prostate cells using semi-quantitative RT-PCR and LDL uptake assays. LDLR mRNA expression and LDL uptake by LDLR were down-regulated in the presence of exogenous LDL or whole serum in the normal prostate cells, but not in the prostate cancer cells. Addition of exogenous cholesterol down-regulated both LDLR and a potent regulator of the ldlr promoter, sterol regulatory element binding protein 2 (SREBP2), in normal cells but not in cancer cells. PGE2 synthesis in prostate cancer cells was significantly increased in response to LDL. Our study suggests that over-production of LDLR is an important mechanism in cancer cells for obtaining more essential fatty acids through LDLR endocytosis, allowing increased synthesis of prostaglandins, which subsequently stimulate cell growth. The data also suggest that the sterol regulatory element and SREBP2 play a role in the loss of sterol feedback regulation in cancer cells.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2001        PMID: 11149418     DOI: 10.1002/1097-0215(20010101)91:1<41::aid-ijc1009>3.0.co;2-2

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  63 in total

1.  HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion.

Authors:  Yoshitaka Sekine; Kazuhiro Suzuki; Alan T Remaley
Journal:  Prostate       Date:  2010-10-26       Impact factor: 4.104

2.  Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai.

Authors:  Roman Corral; Juan Pablo Lewinger; David Van Den Berg; Amit D Joshi; Jian-Min Yuan; Manuela Gago-Dominguez; Victoria K Cortessis; Malcolm C Pike; David V Conti; Duncan C Thomas; Christopher K Edlund; Yu-Tang Gao; Yong-Bing Xiang; Wei Zhang; Yu-Chen Su; Mariana C Stern
Journal:  Int J Cancer       Date:  2014-01-13       Impact factor: 7.396

3.  Role of cholesterol in the development and progression of breast cancer.

Authors:  Gemma Llaverias; Christiane Danilo; Isabelle Mercier; Kristin Daumer; Franco Capozza; Terence M Williams; Federica Sotgia; Michael P Lisanti; Philippe G Frank
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

4.  Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins.

Authors:  Mohana Roy; Hsing-Jien Kung; Paramita M Ghosh
Journal:  Am J Cancer Res       Date:  2011-03-28       Impact factor: 6.166

5.  Elucidating the structural organization of a novel low-density lipoprotein nanoparticle reconstituted with docosahexaenoic acid.

Authors:  Rohit S Mulik; Hui Zheng; Kumar Pichumani; James Ratnakar; Qiu-Xing Jiang; Ian R Corbin
Journal:  Chem Phys Lipids       Date:  2017-03-22       Impact factor: 3.329

6.  "Skittish" Abca2 knockout mice display tremor, hyperactivity, and abnormal myelin ultrastructure in the central nervous system.

Authors:  Jody T Mack; Vladimir Beljanski; Athena M Soulika; Danyelle M Townsend; Carol B Brown; Warren Davis; Kenneth D Tew
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

Review 7.  Learning from biology: synthetic lipoproteins for drug delivery.

Authors:  Huang Huang; William Cruz; Juan Chen; Gang Zheng
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-10-24

8.  Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness.

Authors:  Shuhua Yue; Junjie Li; Seung-Young Lee; Hyeon Jeong Lee; Tian Shao; Bing Song; Liang Cheng; Timothy A Masterson; Xiaoqi Liu; Timothy L Ratliff; Ji-Xin Cheng
Journal:  Cell Metab       Date:  2014-03-04       Impact factor: 27.287

9.  Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion.

Authors:  Iara F Kretzer; Durvanei A Maria; Raul C Maranhão
Journal:  Cell Oncol (Dordr)       Date:  2012-10-03       Impact factor: 6.730

Review 10.  Cholesterol as a potential target for castration-resistant prostate cancer.

Authors:  Alexis L Twiddy; Carlos G Leon; Kishor M Wasan
Journal:  Pharm Res       Date:  2010-08-04       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.